If you made any changes in Pure these will be visible here soon.

Personal profile


Professor Morand is Head of the School of Clinical Sciences at Monash Health, Monash University's largest clinical school, and a physician-scientist. 

He is a clinical rheumatologist, and Head of the Monash Health Rheumatology Unit, the largest in Australia. He specialises in research and clinical care of systemic lupus erythematosus, as well as complex rheumatic diseases and rheumatoid arthritis. He is founder of the Monash Lupus Clinic, Australia's largest research-grounded clinic for patients with SLE, a founding member of the Australian Lupus Registry & Biobank, and Chair of the AsiaPacific Lupus Collaboration. 

His lab at Monash has studied the biology of glucocorticoids in rheumatic disease and lupus since 1996. 

Research interests

Professor Morand's is a physician-scientist whose key interests are clinical outcome measurement and biological profiling in SLE, and the actions of glucocorticoid induced proteins on the immune system. 

His group has pioneered the development of treat-to-target outcome measures in SLE, via the AsiaPacific Lupus Collaboration, which has over 1800 patients under study. 

Biomarker studies in SLE are also a major interest, with 000s of samples linked to longitudinal clinical data archived in the Australian Lupus Registry & Biobank, headquartered at Monash. 

His lab discovered the role in rheumatic disease of multiple important glucocorticoid-regulated proteins. Most recently his group defined the role of GILZ in RA, Th17 pathways, B cell activation, and lupus, and are working on exploiting its actions to develop a safe glucocorticoid mimic. His lab also works on innate immunity including the actions of the unique pro-inflammatory protein, MIF. 

Clinical activities

Professor Morand is Head of Rheumatology, Monash Health. He works in clinics servicing lupus, rheumatoid arthritis, and complex rheumatology cases, and undertakes ward duty inpatient care in the largest service in the country. 


Advisory expertise and research collaboration experience with international biotech and Pharma companies including AstraZeneca, Janssen, BMS, UCB, Pfizer, Eli Lilly, GSK, CSL. 


Special interests include Lupus / SLE outcome measures, trials, translational research and biomarkers. 

Community service

Professor Morand is a Board member of Rare Voices Australia, has served on the board of the Australian Rheumatology Association and is a member of the Scientific Advisory Board of the ARA Research Trust. 


  • Systemic Lupus Erythematosus
  • glucocorticoids
  • Lupus
  • SLE
  • RA
  • GILZ
  • MIF
  • Rheumatoid Arthritis
  • Rheumatology
  • outcome measures
  • Clinical Trials
  • Translational Research
  • Cytokines

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2000 2022

Research Output 1990 2019

Analysis of serum interleukin(IL)-1α, IL-1β and IL-18 in patients with systemic sclerosis

Lin, E., Vincent, F. B., Sahhar, J., Ngian, G-S., Kandane-Rathnayake, R., Mende, R., Morand, E. F., Lang, T. & Harris, J., 1 Jan 2019, In : Clinical and Translational Immunology. 8, 4, 11 p., e1045.

Research output: Contribution to journalArticleResearchpeer-review

Open Access

Development of the Asia Pacific Lupus Collaboration cohort

Kandane-Rathnayake, R., Golder, V., Louthrenoo, W., Luo, S. F., Jan Wu, Y. J., Li, Z., An, Y., Lateef, A., Sockalingam, S., Navarra, S. V., Zamora, L., Hamijoyo, L., Katsumata, Y., Harigai, M., Chan, M., O’Neill, S., Goldblatt, F., Hao, Y., Zhang, Z., Al-Saleh, J. & 8 othersKhamashta, M., Takeuchi, T., Tanaka, Y., Bae, S. C., Sing Lau, C., Hoi, A., Nikpour, M. & Morand, E. F., 1 Mar 2019, In : International Journal of Rheumatic Diseases. 22, 3, p. 425-433 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Effect of storage duration on cytokine stability in human serum and plasma

Vincent, F. B., Nim, H. T., Lee, J. P. W., Morand, E. F. & Harris, J., Jan 2019, In : Cytokine. 113, p. 453-457 5 p.

Research output: Contribution to journalArticleResearchpeer-review

Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus

Oon, S., Huq, M., Golder, V., Ong, P. X., Morand, E. F. & Nikpour, M., 1 May 2019, In : Annals of the Rheumatic Diseases. 78, 5, p. 29-633 5 p.

Research output: Contribution to journalArticleResearchpeer-review


Dean's Award for Research (Enterprise)

Eric Morand (Recipient), 1 Aug 2018

Prize: Prize (including medals and awards)

Distinguished Innovator Award

Eric Morand (Recipient), 2015

Prize: National/international honour

Parr Prize for Research

Eric Morand (Recipient), 2001

Prize: Prize (including medals and awards)

Supervisor of the Year

Eric Morand (Recipient), 2011

Prize: Prize (including medals and awards)